 | • レポートコード：MRC2-11QY11438 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は併用抗体療法のグローバル市場について調査・分析したレポートです。種類別（化学療法/抗体、抗体/抗体、コンジュゲート抗体、二重特異性抗体）市場規模、用途別（病院、がん研究所、クリニック、ASC）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別併用抗体療法の競争状況、市場シェア ・世界の併用抗体療法市場：種類別市場規模 2015年-2020年（化学療法/抗体、抗体/抗体、コンジュゲート抗体、二重特異性抗体） ・世界の併用抗体療法市場：種類別市場規模予測 2021年-2026年（化学療法/抗体、抗体/抗体、コンジュゲート抗体、二重特異性抗体） ・世界の併用抗体療法市場：用途別市場規模 2015年-2020年（病院、がん研究所、クリニック、ASC） ・世界の併用抗体療法市場：用途別市場規模予測 2021年-2026年（病院、がん研究所、クリニック、ASC） ・北米の併用抗体療法市場分析：米国、カナダ ・ヨーロッパの併用抗体療法市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの併用抗体療法市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の併用抗体療法市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの併用抗体療法市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Biogen、Roche Holdings、Seattle Genetics、Amgen、Bristol-Myers Squibb、Eli Lilly、Novartis、Sanofi、Celgene、Genmab ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Combination antibody therapy is receiving higher recognition from the oncological branch of medical science research. This is primarily due to the growing use of combination therapy over single drug treatments such as radiation or chemotherapy. In addition, companies that manufacture combination antibody drugs are actively focusing on developing superior drugs that will deliver standout results. Factors such as encouraging government policies, growing concerns over higher cancer prevalence worldwide, and increasing research and development activities coupled with heavier investments are expected to boost the overall market growth in the near future. Likewise, healthy R&D pipelines are leading towards higher product offerings and also propelling the growth of global combination antibody therapy market to a significant extent.
The first and foremost reason for fueling the growth of the chemotherapy/antibody segment is the rise in the rates of cancer across the globe. Cancer is the second leading cause of death globally after cardiovascular disease. The proportion of deaths around the world due to cancer has increased remarkably in the last few years.
Market Analysis and Insights: Global Combination Antibody Therapy Market
The global Combination Antibody Therapy market size is projected to reach US$ 37200 million by 2026, from US$ 34240 million in 2020, at a CAGR of 8.0%% during 2021-2026.
Global Combination Antibody Therapy Scope and Market Size
Combination Antibody Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Combination Antibody Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Biogen
Roche Holdings
Seattle Genetics
Amgen
Bristol-Myers Squibb
Eli Lilly
Novartis
Sanofi
Celgene
Genmab
Market segment by Type, the product can be split into
Chemotherapy/Antibody
Antibody/Antibody
Conjugated Antibodies
Bispecific Antibodies
Market segment by Application, split into
Hospitals
Cancer Research Institutes
Clinics
ASCs
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Combination Antibody Therapy Revenue
1.4 Market by Type
1.4.1 Global Combination Antibody Therapy Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy/Antibody
1.4.3 Antibody/Antibody
1.4.4 Conjugated Antibodies
1.4.5 Bispecific Antibodies
1.5 Market by Application
1.5.1 Global Combination Antibody Therapy Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Cancer Research Institutes
1.5.4 Clinics
1.5.5 ASCs
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Combination Antibody Therapy Market Perspective (2015-2026)
2.2 Global Combination Antibody Therapy Growth Trends by Regions
2.2.1 Combination Antibody Therapy Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Combination Antibody Therapy Historic Market Share by Regions (2015-2020)
2.2.3 Combination Antibody Therapy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Combination Antibody Therapy Market Growth Strategy
2.3.6 Primary Interviews with Key Combination Antibody Therapy Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Combination Antibody Therapy Players by Market Size
3.1.1 Global Top Combination Antibody Therapy Players by Revenue (2015-2020)
3.1.2 Global Combination Antibody Therapy Revenue Market Share by Players (2015-2020)
3.1.3 Global Combination Antibody Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Combination Antibody Therapy Market Concentration Ratio
3.2.1 Global Combination Antibody Therapy Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Combination Antibody Therapy Revenue in 2019
3.3 Combination Antibody Therapy Key Players Head office and Area Served
3.4 Key Players Combination Antibody Therapy Product Solution and Service
3.5 Date of Enter into Combination Antibody Therapy Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Combination Antibody Therapy Historic Market Size by Type (2015-2020)
4.2 Global Combination Antibody Therapy Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Combination Antibody Therapy Market Size by Application (2015-2020)
5.2 Global Combination Antibody Therapy Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Combination Antibody Therapy Market Size (2015-2020)
6.2 Combination Antibody Therapy Key Players in North America (2019-2020)
6.3 North America Combination Antibody Therapy Market Size by Type (2015-2020)
6.4 North America Combination Antibody Therapy Market Size by Application (2015-2020)
7 Europe
7.1 Europe Combination Antibody Therapy Market Size (2015-2020)
7.2 Combination Antibody Therapy Key Players in Europe (2019-2020)
7.3 Europe Combination Antibody Therapy Market Size by Type (2015-2020)
7.4 Europe Combination Antibody Therapy Market Size by Application (2015-2020)
8 China
8.1 China Combination Antibody Therapy Market Size (2015-2020)
8.2 Combination Antibody Therapy Key Players in China (2019-2020)
8.3 China Combination Antibody Therapy Market Size by Type (2015-2020)
8.4 China Combination Antibody Therapy Market Size by Application (2015-2020)
9 Japan
9.1 Japan Combination Antibody Therapy Market Size (2015-2020)
9.2 Combination Antibody Therapy Key Players in Japan (2019-2020)
9.3 Japan Combination Antibody Therapy Market Size by Type (2015-2020)
9.4 Japan Combination Antibody Therapy Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Combination Antibody Therapy Market Size (2015-2020)
10.2 Combination Antibody Therapy Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Combination Antibody Therapy Market Size by Type (2015-2020)
10.4 Southeast Asia Combination Antibody Therapy Market Size by Application (2015-2020)
11 India
11.1 India Combination Antibody Therapy Market Size (2015-2020)
11.2 Combination Antibody Therapy Key Players in India (2019-2020)
11.3 India Combination Antibody Therapy Market Size by Type (2015-2020)
11.4 India Combination Antibody Therapy Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Combination Antibody Therapy Market Size (2015-2020)
12.2 Combination Antibody Therapy Key Players in Central & South America (2019-2020)
12.3 Central & South America Combination Antibody Therapy Market Size by Type (2015-2020)
12.4 Central & South America Combination Antibody Therapy Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Biogen
13.1.1 Biogen Company Details
13.1.2 Biogen Business Overview
13.1.3 Biogen Combination Antibody Therapy Introduction
13.1.4 Biogen Revenue in Combination Antibody Therapy Business (2015-2020))
13.1.5 Biogen Recent Development
13.2 Roche Holdings
13.2.1 Roche Holdings Company Details
13.2.2 Roche Holdings Business Overview
13.2.3 Roche Holdings Combination Antibody Therapy Introduction
13.2.4 Roche Holdings Revenue in Combination Antibody Therapy Business (2015-2020)
13.2.5 Roche Holdings Recent Development
13.3 Seattle Genetics
13.3.1 Seattle Genetics Company Details
13.3.2 Seattle Genetics Business Overview
13.3.3 Seattle Genetics Combination Antibody Therapy Introduction
13.3.4 Seattle Genetics Revenue in Combination Antibody Therapy Business (2015-2020)
13.3.5 Seattle Genetics Recent Development
13.4 Amgen
13.4.1 Amgen Company Details
13.4.2 Amgen Business Overview
13.4.3 Amgen Combination Antibody Therapy Introduction
13.4.4 Amgen Revenue in Combination Antibody Therapy Business (2015-2020)
13.4.5 Amgen Recent Development
13.5 Bristol-Myers Squibb
13.5.1 Bristol-Myers Squibb Company Details
13.5.2 Bristol-Myers Squibb Business Overview
13.5.3 Bristol-Myers Squibb Combination Antibody Therapy Introduction
13.5.4 Bristol-Myers Squibb Revenue in Combination Antibody Therapy Business (2015-2020)
13.5.5 Bristol-Myers Squibb Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview
13.6.3 Eli Lilly Combination Antibody Therapy Introduction
13.6.4 Eli Lilly Revenue in Combination Antibody Therapy Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 Novartis
13.7.1 Novartis Company Details
13.7.2 Novartis Business Overview
13.7.3 Novartis Combination Antibody Therapy Introduction
13.7.4 Novartis Revenue in Combination Antibody Therapy Business (2015-2020)
13.7.5 Novartis Recent Development
13.8 Sanofi
13.8.1 Sanofi Company Details
13.8.2 Sanofi Business Overview
13.8.3 Sanofi Combination Antibody Therapy Introduction
13.8.4 Sanofi Revenue in Combination Antibody Therapy Business (2015-2020)
13.8.5 Sanofi Recent Development
13.9 Celgene
13.9.1 Celgene Company Details
13.9.2 Celgene Business Overview
13.9.3 Celgene Combination Antibody Therapy Introduction
13.9.4 Celgene Revenue in Combination Antibody Therapy Business (2015-2020)
13.9.5 Celgene Recent Development
13.10 Genmab
13.10.1 Genmab Company Details
13.10.2 Genmab Business Overview
13.10.3 Genmab Combination Antibody Therapy Introduction
13.10.4 Genmab Revenue in Combination Antibody Therapy Business (2015-2020)
13.10.5 Genmab Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Combination Antibody Therapy Key Market Segments
Table 2. Key Players Covered: Ranking by Combination Antibody Therapy Revenue
Table 3. Ranking of Global Top Combination Antibody Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Combination Antibody Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy/Antibody
Table 6. Key Players of Antibody/Antibody
Table 7. Key Players of Conjugated Antibodies
Table 8. Key Players of Bispecific Antibodies
Table 9. Global Combination Antibody Therapy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Combination Antibody Therapy Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Combination Antibody Therapy Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Combination Antibody Therapy Market Share by Regions (2015-2020)
Table 13. Global Combination Antibody Therapy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Combination Antibody Therapy Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Combination Antibody Therapy Market Growth Strategy
Table 19. Main Points Interviewed from Key Combination Antibody Therapy Players
Table 20. Global Combination Antibody Therapy Revenue by Players (2015-2020) (Million US$)
Table 21. Global Combination Antibody Therapy Market Share by Players (2015-2020)
Table 22. Global Top Combination Antibody Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Combination Antibody Therapy as of 2019)
Table 23. Global Combination Antibody Therapy by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Combination Antibody Therapy Product Solution and Service
Table 26. Date of Enter into Combination Antibody Therapy Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 29. Global Combination Antibody Therapy Market Size Share by Type (2015-2020)
Table 30. Global Combination Antibody Therapy Revenue Market Share by Type (2021-2026)
Table 31. Global Combination Antibody Therapy Market Size Share by Application (2015-2020)
Table 32. Global Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 33. Global Combination Antibody Therapy Market Size Share by Application (2021-2026)
Table 34. North America Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 36. North America Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 37. North America Combination Antibody Therapy Market Share by Type (2015-2020)
Table 38. North America Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 39. North America Combination Antibody Therapy Market Share by Application (2015-2020)
Table 40. Europe Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 42. Europe Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Combination Antibody Therapy Market Share by Type (2015-2020)
Table 44. Europe Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Combination Antibody Therapy Market Share by Application (2015-2020)
Table 46. China Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 47. China Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 48. China Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 49. China Combination Antibody Therapy Market Share by Type (2015-2020)
Table 50. China Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 51. China Combination Antibody Therapy Market Share by Application (2015-2020)
Table 52. Japan Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 54. Japan Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Combination Antibody Therapy Market Share by Type (2015-2020)
Table 56. Japan Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Combination Antibody Therapy Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 60. Southeast Asia Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Combination Antibody Therapy Market Share by Type (2015-2020)
Table 62. Southeast Asia Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Combination Antibody Therapy Market Share by Application (2015-2020)
Table 64. India Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 65. India Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 66. India Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 67. India Combination Antibody Therapy Market Share by Type (2015-2020)
Table 68. India Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 69. India Combination Antibody Therapy Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Combination Antibody Therapy Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Combination Antibody Therapy Market Share (2019-2020)
Table 72. Central & South America Combination Antibody Therapy Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Combination Antibody Therapy Market Share by Type (2015-2020)
Table 74. Central & South America Combination Antibody Therapy Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Combination Antibody Therapy Market Share by Application (2015-2020)
Table 76. Biogen Company Details
Table 77. Biogen Business Overview
Table 78. Biogen Product
Table 79. Biogen Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 80. Biogen Recent Development
Table 81. Roche Holdings Company Details
Table 82. Roche Holdings Business Overview
Table 83. Roche Holdings Product
Table 84. Roche Holdings Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 85. Roche Holdings Recent Development
Table 86. Seattle Genetics Company Details
Table 87. Seattle Genetics Business Overview
Table 88. Seattle Genetics Product
Table 89. Seattle Genetics Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 90. Seattle Genetics Recent Development
Table 91. Amgen Company Details
Table 92. Amgen Business Overview
Table 93. Amgen Product
Table 94. Amgen Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 95. Amgen Recent Development
Table 96. Bristol-Myers Squibb Company Details
Table 97. Bristol-Myers Squibb Business Overview
Table 98. Bristol-Myers Squibb Product
Table 99. Bristol-Myers Squibb Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 100. Bristol-Myers Squibb Recent Development
Table 101. Eli Lilly Company Details
Table 102. Eli Lilly Business Overview
Table 103. Eli Lilly Product
Table 104. Eli Lilly Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 105. Eli Lilly Recent Development
Table 106. Novartis Company Details
Table 107. Novartis Business Overview
Table 108. Novartis Product
Table 109. Novartis Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 110. Novartis Recent Development
Table 111. Sanofi Business Overview
Table 112. Sanofi Product
Table 113. Sanofi Company Details
Table 114. Sanofi Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 115. Sanofi Recent Development
Table 116. Celgene Company Details
Table 117. Celgene Business Overview
Table 118. Celgene Product
Table 119. Celgene Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 120. Celgene Recent Development
Table 121. Genmab Company Details
Table 122. Genmab Business Overview
Table 123. Genmab Product
Table 124. Genmab Revenue in Combination Antibody Therapy Business (2015-2020) (Million US$)
Table 125. Genmab Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Combination Antibody Therapy Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy/Antibody Features
Figure 3. Antibody/Antibody Features
Figure 4. Conjugated Antibodies Features
Figure 5. Bispecific Antibodies Features
Figure 6. Global Combination Antibody Therapy Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Cancer Research Institutes Case Studies
Figure 9. Clinics Case Studies
Figure 10. ASCs Case Studies
Figure 11. Combination Antibody Therapy Report Years Considered
Figure 12. Global Combination Antibody Therapy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Combination Antibody Therapy Market Share by Regions: 2020 VS 2026
Figure 14. Global Combination Antibody Therapy Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Combination Antibody Therapy Market Share by Players in 2019
Figure 17. Global Top Combination Antibody Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Combination Antibody Therapy as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Combination Antibody Therapy Revenue in 2019
Figure 19. North America Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Combination Antibody Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Bottom-up and Top-down Approaches for This Report
Figure 27. Data Triangulation
Figure 28. Key Executives Interviewed
モノクローナル抗体療法の世界市場（～2026年） Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…- 次世代抗体療法の世界市場（～2026年） The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period. Market Analysis and Insights: Global Next Generation Anti…
- B3GL2抗体の世界市場（～2026年） Market Analysis and Insights: Global B3GL2 Antibody Market The global B3GL2 Antibody market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global B3GL2 Antibody Scope and Market Size B3GL2 Antibody market is segmented by Type, and …
- モノクローナル抗体ベース製品の世界市場（～2026年） Monoclonal antibody therapeutics is a type of immunotherapy in which monoclonal antibodies are used so that they can bind monospecifically to specific cells and proteins. This treatment stimulates the immune system of patients to attack the foreign cells which cause the disease. Monoclonal antibodie…
- C1GLT抗体の世界市場（～2026年） Market Analysis and Insights: Global C1GLT Antibody Market The global C1GLT Antibody market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global C1GLT Antibody Scope and Market Size C1GLT Antibody market is segmented by Type, and …